Articles

To attack costs, Lilly accelerates R&D

With President Barack Obama looking to squeeze a bit more revenue out of the pharmaceutical industry, the stakes just keep
getting higher for Eli Lilly and Co.’s efforts to develop drugs faster and cheaper.

Read More

Perils of non-family managers

A former Toyota exec blasts non-family managers for the company’s problems. Are some Indianapolis-area companies better-
or worse-off after families relinquished control?

Read More

Lilly asks shareholders to lower takeover barrier

Eli Lilly and Co. directors have recommended that shareholders toss out the
drugmaker's most potent protection against unwanted takeovers: an 80-percent supermajority vote threshold for any shareholder
mutiny to succeed.

Read More

Pfizer’s Viagra patent partially rejected in Lilly fight

The patent on impotence drug Viagra was partially rejected after the U.S. Patent and Trademark Office said it wasn’t different
enough from a Chinese herb known as Horny Goat Weed. The patent was key to an infringement suit Pfizer filed in 2002 against
Eli Lilly and Co. over its rival Cialis drug.

Read More

Indy without Lilly, the 500?

An Indiana University prof thinks Indianapolis should anticipate a future without Indianapolis Motor Speedway, and a potentially
reduced Eli Lilly and Co.

Read More

Q&A: Dr. Kristine Courtney

Dr. Kristine Courtney, Eli Lilly and Co.’s senior director of corporate health services, describes
how and why the company spent two years making its clinics some of the first to electronically swap patient records with
a local hospital database.

Read More